The Frequency of SMN1, SMN2 Copy Numbers in 246 Turkish Cases Analyzed with MLPA Method

Abstract

This study aimed to define the copy numbers of SMN1 and SMN2 genes and the diagnosis rate and carrier frequency of spinal muscular atrophy (SMA) in the Thrace region of Turkey. In this study, the frequency of deletions in exons 7 and 8 in the SMN1 gene and SMN2 copy numbers were investigated. A total of 133 cases with the preliminary diagnosis of SMA and 113 cases with the suspicion of being an SMA carrier from independent families were analyzed by multiplex ligation-dependent probe amplification method for SMN1 and SMN2 gene copy numbers.

SMN1 homozygous deletions were detected in 34 patients (25.5%) of 133 cases with the suspicion of SMA. Cases diagnosed with SMA type I was 41.17% (14/34), 29.4% (10/34) with type II, 26.4% (9/34) with type III, and 2.94% (1/34) with type IV. The SMA carrier rate was 46.01% in 113 cases. In 34 SMA cases, SMN2 copy numbers were: two copies – 28 cases (82.3%), three copies – 6 cases (17.6%). SMN2 homozygous deletions were detected in 15% (17/113) of carrier analysis cases. The consanguinity rate of the parents was 23.5% in SMA diagnosed cases. In this study, we had a 25.5% of SMA diagnosis rate and 46% SMA carrier frequency. The current study also showed the relatively low consanguinity rate of the Thrace region, with 23.5% according to the east of Turkey.

Keywords

spinal muscular atrophy - SMN1 - SMN2 - copy number - consanguinity

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Publikationsverlauf

Artikel online veröffentlicht:
16. Juni 2023

• References

• 1 Figlewicz DA, Orrell RW. The genetics of motor neuron diseases. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4 (04) 225-231
• 2 Harms MB, Allred P, Gardner Jr R. et al. Dominant spinal muscular atrophy with lower extremity predominance: linkage to 14q32. Neurology 2010; 75 (06) 539-546
• 3 Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal muscular atrophy. Semin Pediatr Neurol 2021; 37: 100878
• 4 Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers 2022; 8 (01) 52
• 5 Singh NN, Singh RN. How RNA structure dictates the usage of a critical exon of spinal muscular atrophy gene. Biochim Biophys Acta Gene Regul Mech 2019; 1862 (11-12): 194403
• 6 Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin 2015; 33 (04) 831-846
• 7 Horne C, Young PJ. Is RNA manipulation a viable therapy for spinal muscular atrophy?. J Neurol Sci 2009; 287 (1-2): 27-31
• 8 Hwang H, Lee JH, Choi YC. Clinical characteristics of spinal muscular atrophy in Korea confirmed by genetic analysis. Yonsei Med J 2017; 58 (05) 1051-1054
• 9 Prior TW, Snyder PJ, Rink BD. et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A 2010; 152A [phone]
• 10 Arnold ES, Fischbeck KH. Spinal muscular atrophy. Handb Clin Neurol 2018; 148: 591-601
• 11 Finkel RS, McDermott MP, Kaufmann P. et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 2014; 83 (09) 810-817
• 12 Lally C, Jones C, Farwell W, Reyna SP, Cook SF, Flanders WD. Indirect estimation of the prevalence of spinal muscular atrophy type I, II, and III in the United States. Orphanet J Rare Dis 2017; 12 (01) 175
• 13 Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol 1999; 3 (02) 49-51
• 14 Noguchi Y, Onishi A, Nakamachi Y. et al. Telomeric region of the spinal muscular atrophy locus is susceptible to structural variations. Pediatr Neurol 2016; 58: 83-89
• 15 Chen X, Sanchis-Juan A, French CE. et al; NIHR BioResource. Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data. Genet Med 2020; 22 (05) 945-953
• 16 Vijzelaar R, Snetselaar R, Clausen M. et al. The frequency of SMN gene variants lacking exon 7 and 8 is highly population dependent. PLoS One 2019; 14 (07) e0220211
• 17 Li C, Geng Y, Zhu X. et al. The prevalence of spinal muscular atrophy carrier in China: Evidences from epidemiological surveys. Medicine (Baltimore) 2020; 99 (05) e18975
• 18 Rashnonejad A, Onay H, Atik T. et al. Molecular genetic analysis of survival motor neuron gene in 460 Turkish cases with suspicious spinal muscular atrophy disease. Iran J Child Neurol 2016; 10 (04) 30-35
• 19 Mailman MD, Heinz JW, Papp AC. et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 2002; 4 (01) 20-26
• 20 Harada Y, Sutomo R, Sadewa AH. et al. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity. J Neurol 2002; 249 (09) 1211-1219
• 21 Wirth B, Brichta L, Hahnen E. Spinal muscular atrophy and therapeutic prospects. Prog Mol Subcell Biol 2006; 44: 109-132
• 22 Ogino S, Gao S, Leonard DG, Paessler M, Wilson RB. Inverse correlation between SMN1 and SMN2 copy numbers: evidence for gene conversion from SMN2 to SMN1. Eur J Hum Genet 2003; 11 (03) 275-277
• 23 Bora-Tatar G, Yesbek-Kaymaz A, Bekircan-Kurt CE, Erdem-Özdamar S, Erdem-Yurter H. Spinal muscular atrophy type III: molecular genetic characterization of Turkish patients. Eur J Med Genet 2015; 58 (12) 654-658
• 24 Derakhshandeh-Peykar P, Esmaili M, Ousati-Ashtiani Z. et al. Molecular analysis of the SMN1 and NAIP genes in Iranian patients with spinal muscular atrophy. Ann Acad Med Singap 2007; 36 (11) 937-941
• 25 Savas S, Eraslan S, Kantarci S. et al. Prenatal prediction of childhood-onset spinal muscular atrophy (SMA) in Turkish families. Prenat Diagn 2002; 22 (08) 703-709
• 26 Sun Y, Kong X, Zhao Z, Zhao X. Mutation analysis of 419 family and prenatal diagnosis of 339 cases of spinal muscular atrophy in China. BMC Med Genet 2020; 21 (01) 133